To Be or Not To Be: That is the Abstract Question, Naturally

In a trilogy of decisions since 2010, the Supreme Court changed its interpretation of the judicial exceptions to patentability, namely laws of nature, natural phenomena, and abstract ideas. Bilski v. Kappos, 561 U.S.593, 601, 130 S. Ct. 3218, 3225, 95 USPQ2d 1001, 1005-06 (2010); Association for Molecular Pathology v. Myriad Genetics, Inc. 569 U.S. _, 133 S. Ct. 2107, 2116, 106 USPQ2d 1972, 1979 (2013); and Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 573 U.S. _, 134 S. Ct. 2347, 2354, 110 USPQ2d 1976, 1980 (2014).

In this seminar, Aasheesh Shravah and Amy Goldsmith, Intellectual Property Practice Attorneys at Tarter Krinsky & Drogin LLP, discuss the effect of these decisions on the patentability of biotech, computer software and business methods. How the U.S. Patent Office has responded will also be reviewed as will the various district court and Federal Circuit decisions interpreting the USPTO Guidelines and the Bilski/Myriad/Alice trilogy. 

1. Understand the USPTO Guidelines for biotech, computer software and business method patents
2. Recognize what the USPTO has deemed is an allowable application
3. Answer the question: “What is the test for patent eligibility and how has it been interpreted by the district courts and the Federal Circuit?”
4. Identify the interplay between patents, copyrights and trade secrets

Access Live Webcast:

Most Lawline members have unlimited access to all 350+ annual live webcasts and 1,500 hours of on-demand courses. Login here using your member ID and password. Not a member? Join here. If you are only interested in purchasing this course, click add course to cart in upper right corner. Call or email with questions: 1-877-518-0660